Integration of Novel Agents Into the Care of Patients with Multiple Myeloma

Correction Clinical Cancer Correction: Integration of Novel Agents into Research the Care of Patients with Multiple Myeloma

In this article (Clin Cancer Res 2016;22(22):5443–52), which was published in the November 15, 2016, issue of Clinical Cancer Research (1), the author alerted us to errors in Fig. 2 that were introduced during the production process. Specifically, in the box "Four or more prior lines of therapy" located at the top right of the figure, "carfilzomib/daratumumab" should read "carfilzomib, daratumumab." In addition, in the box "Four or more prior lines of therapy" located at the bottom right of the figure, "carfilzomib/dex/daratumumab" should read "carfilzomib/dex, daratumumab." The corrected version of Fig. 2 is below. These corrections are reflected in the current version of the article. The publisher regrets this error.

Figure 2. Relapsed disease Evidence-based algorithm for treatment of patients with relapsed and/or refractory myeloma using our currently One–three prior lines of therapy Four or more prior lines of therapy approved novel agents. This diagram provides Frail: bortezomib ± dex, lenalidomide/dex, Frail: bortezomib ± dex, carfilzomib, daratumumab, an overview of just some of the considerations and pomalidomide ± dex, ixazomib/lenalidomide/dex ixazomib/lenalidomide/dex, lenalidomide/dex, options that are involved in management of patients with pomalidomide ± dex relapsed and/or refractory disease. Please Fit: carfilzomib/dex, carfilzomib/lenalidomide/dex, Fit: bortezomib/pegylated liposomal doxorubicin ± consult the text for further details about the use of this daratumumab/bortezomib/dex, dex, carfilzomib/dex, daratumumab/lenalidomide/dex, daratumumab/bortezomib/dex, approach, which will need to be individualized to the elotuzumab/lenalidomide/dex, daratumumab/lenalidomide/dex, molecular characteristics of each patient's disease (Fig. 1). ixazomib/lenalidomide/dex, ixazomib/lenalidomide/dex, The patient's prior exposure to and tolerance of these panobinostat/bortezomib/dex panobinostat/bortezomib/dex drug classes need consideration, as do their comorbidities. With regard to the latter, some Recently bortezomib refractory suggestions are provided about appropriate options in the fit (pink background) and frail patient (gray background). Also, note that this list includes only One–three prior lines of therapy Four or more prior lines of therapy recently approved, novel single agents and combination Frail: lenalidomide/dex, pomalidomide ± dex Frail: carfilzomib, daratumumab, lenalidomide/dex, regimens, as well as some combinations that will likely be pomalidomide ± dex approved based on already-available phase III data. For Fit: carfilzomib/dex, carfilzomib/lenalidomide/dex, Fit: panobinostat/bortezomib/dex, the sake of brevity, we have not incorporated other drug daratumumab/lenalidomide/dex, daratumumab/lenalidomide/dex classes, such as conventional alkylating agents, which elotuzumab/lenalidomide/dex, panobinostat/bortezomib/dex may be of substantial use in this setting either at standard doses or in the context of high-dose therapy with autologous stem cell rescue. Moreover, other Recently lenalidomide refractory combinations that have been reported to show encouraging outcomes, such as carfilzomib with pomalidomide and dexamethasone, are not included due One–three prior lines of therapy Four or more prior lines of therapy to the lack of phase III data. Thus, this algorithm should Frail: bortezomib ± dex Frail: bortezomib ± dex, carfilzomib, daratumumab, pomalidomide ± dex not be taken as a representation of the full array of available therapies in this setting. "Carfilzomib" refers to Fit: bortezomib/pegylated liposomal doxorubicin ± Fit: bortezomib/pegylated liposomal doxorubicin ± the use of this drug as a single agent at the standard dose dex, carfilzomib/dex, dex, daratumumab/bortezomib/dex, (20 mg/m2 on days 1, 2, 8, 9, 15, and 15 in cycle 1, and then daratumumab/bortezomib/dex, panobinostat/bortezomib/dex panobinostat/bortezomib/dex, pomalidomide ± dex 27 mg/m2 on the same days starting cycle 2), whereas "Carfilzomib/dex" refers to its use at a high dose, which is detailed in Table 1. As in Fig. 1, the options are presented Recently dual bortezomib and lenalidomide refractory alphabetically, and their order should not be construed as a suggestion of their appropriate sequencing, as such studies have not been performed. Finally, providers will One–three prior lines of therapy Four or more prior lines of therapy need to consider the populations for which each of these Frail: pomalidomide ± dex Frail: carfilzomib, daratumumab, regimens have been approved, as detailed in Table 1, in pomalidomide ± dex making their treatment decisions. For example, Fit: Fit: carfilzomib/dex, panobinostat/bortezomib/dex carfilzomib/dex, daratumumab, panobinostat/ panobinostat with bortezomib and dexamethasone (dex) bortezomib/dex is approved for patients with two ormore prior therapies, and this regimen is, therefore, appropriate as a third-line © 2016 American Association for Cancer Research or later treatment, but not yet as a second-line choice.

Reference 1. Orlowski RZ, Lonial S. Integration of novel agents into the care of patients with multiple myeloma. Clin Cancer Res 2016;22:5443–52.

Published online May 15, 2017. doi: 10.1158/1078-0432.CCR-17-0064 Ó2017 American Association for Cancer Research.

www.aacrjournals.org 2605

Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2017 American Association for Cancer Research. Correction: Integration of Novel Agents into the Care of Patients with Multiple Myeloma

Clin Cancer Res 2017;23:2605.

Updated version Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/23/10/2605

Cited articles This article cites 1 articles, 1 of which you can access for free at: http://clincancerres.aacrjournals.org/content/23/10/2605.full#ref-list-1

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at Subscriptions [email protected].

Permissions To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/23/10/2605. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.